U.S. Personal Products Stock News

JPMorgan Chase (NYSE:JPM) is co-leading a U.S. banking consortium to launch a shared tokenized deposit network using blockchain for instant settlement and programmable payments. The consortium effort is positioned as a direct challenge to stablecoins and crypto native payment rails as banks move to build their own tokenized infrastructure. In parallel, JPMorgan is reportedly exploring a sizable push into private credit, including a potential multi billion dollar deal for a platform such as...

X-energy, Inc. recently submitted its Xe-100 high-temperature gas-cooled reactor design to enter the United Kingdom’s Generic Design Assessment process, a key step in securing UK regulatory approval for future deployment. This move deepens X-energy’s collaboration with Centrica on up to 6 GW of advanced nuclear capacity and leverages cross-border regulatory cooperation with U.S. authorities to potentially streamline licensing. We’ll now examine how this progress on UK licensing, especially...

Investors may be wondering if Meta Platforms at US$593.00 is starting to look appealing again, or if the stock still carries a premium compared to its fundamentals. The share price has retreated, with the stock down 6.2% over the past week, 3.2% over the past month, 8.8% year to date and 14.7% over the past year. However, it is still up 125.6% over three years and 80.4% over five years. Recent headlines have focused on Meta's push into artificial intelligence tools across its apps, as well...

Recent share performance and what it may signal Advanced Micro Devices (AMD) has seen mixed trading recently, with the stock down 10.9% over the past day and 9.6% over the past week, while remaining higher over the past month and past 3 months. For context, the stock closed at US$466.38, with year to date and 1 year total returns both above 100%, and multi year total returns that are also very large compared with the starting point five years ago. See our latest analysis for Advanced Micro...

If you are wondering whether Exxon Mobil at around US$149.92 is still offering value or starting to look expensive, you are not alone. The stock has returned 3.2% over the last 7 days, 0.8% over the past month, 22.2% year to date and 48.4% over the last year, with a 3 year return of 54.3% and a 5 year return of 189.8%. Recent headlines have focused on Exxon Mobil's role in large scale energy projects and ongoing discussions about capital allocation, including share repurchases and investment...

Recent share performance and business profile Veralto (VLTO) has been under pressure recently, with the stock down about 1% over the past month and roughly 9% over the past 3 months, even as the underlying business continues to generate sizeable revenue and profit. See our latest analysis for Veralto. At a share price of $86.05, Veralto’s recent 4.65% 7 day share price return contrasts with a year to date share price decline of 12.64%. This indicates that momentum has softened following...

In May 2026, Omnicell, Inc. shareholders approved an amendment to the company’s Amended and Restated Certificate of Incorporation at its Annual Meeting, while the company also prepared to present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Together with recent analyst upgrades and a stronger earnings outlook, these governance and investor-relations developments highlight growing confidence in Omnicell’s medication management platform and recurring revenue...

United Airlines Holdings stock snapshot United Airlines Holdings (UAL) stock has been moving in recent months, with a last close of $105.73 and a market value of about $34.1b, inviting closer attention from investors tracking airline exposure. See our latest analysis for United Airlines Holdings. Recent trading has been choppy, with a 7 day share price return down 7.9% after a 90 day share price return of 14.8%. At the same time, the 1 year total shareholder return of 25.5% and 3 year total...

In April 2026, Becton, Dickinson and Company voluntarily initiated worldwide Class II recalls of several Swan-Ganz and Swan-Ganz Jr catheter models after US regulators reported that manufacturing and material changes could cause leaks or breaks at the proximal injectate lumen hub, risking infection, medication loss, or blood loss for patients. With more than half a million devices affected across hospitals in the US and dozens of other countries, the episode highlights how quality control...

Rigetti Computing overview Rigetti Computing (RGTI) has drawn investor attention with its focus on quantum computing hardware and cloud access, while the stock shows mixed short term moves and stronger longer term total returns. See our latest analysis for Rigetti Computing. After a sharp 14.4% decline in the 1 day share price and a 19.03% fall over the past week, Rigetti’s 1 year total shareholder return of 83.33% and very large 3 year total shareholder return suggest longer term momentum...

If you are wondering whether QUALCOMM at around US$215.94 is still offering value after a strong run, the key is to look past the headline price and into how the stock is actually being valued. The share price has seen mixed short term moves, with a decline of 14.0% over the past week, a 12.1% gain over the last 30 days, and returns of 24.8% year to date and 47.7% over the past year. These shifts can change how the market is thinking about both opportunity and risk. These swings are...

Recent share performance and business mix Chubb (CB) has seen a small daily move of 0.04% and a 5.2% gain year to date, with the stock closing at US$326.27. Over the past year the total return is 12.5%. Returns over the past week and month are 4.7% and 1.4%, while performance over the past 3 months is slightly lower, down 0.5%. For longer term holders, the 3 year and 5 year total returns are approximately 7.8x and 11.1x respectively. The company reports annual revenue of US$60.99b and net...

RLX Technology stock performance snapshot RLX Technology (RLX) has drawn fresh attention after recent trading left the stock at US$2.00, with returns down around 10% over the past month and 11% over the past 3 months. For investors tracking the e vapor segment in China, this price level and recent share performance set the context for reviewing RLX Technology’s US$2.47b market value, profitability in reporting currency, and how recent business trends might align with personal risk tolerance...

AGNC Investment (NasdaqGS:AGNC) has approved a new $1b stock repurchase plan running through 2026. The company is actively repositioning its portfolio toward higher coupon agency MBS and stronger interest rate hedging. This follows earlier capital raising activity and marks a shift in how AGNC is choosing to deploy capital. AGNC Investment, trading at around $10.17 per share, enters this new phase after a mixed stretch for the stock, with the share price up 28.3% over the past year but down...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Before deciding whether Align Technology stock looks attractive or not, you probably want to know if the current price around US$167.74 fairly reflects what the business might be worth. Over the short term, the stock has been under pressure, with the share price down 4.1% over the last week and 3.6% over the last month, although it is up 7.5% year to date. The one year and three year returns show declines of 7.1% and 44.9% respectively, with a 72.6% decline over five years. Recent news...

BioCryst Pharmaceuticals recently announced it would present seven abstracts from its hereditary angioedema portfolio at the EAACI 2026 meeting in Istanbul, highlighting new clinical and real-world data for ORLADEYO and its investigational antibody navenibart. This concentrated scientific presence underscores how BioCryst is working to deepen ORLADEYO’s clinical evidence base while advancing navenibart as a potential next-generation prophylactic option for hereditary angioedema. Next, we’ll...

In recent months, Pelagos Insurance Capital has drawn attention after analysts significantly raised earnings estimates, awarding it a top Zacks Rank and highlighting its low price-to-earnings ratio versus peers. At the same time, its role as a capacity provider in The Fidelis Partnership’s new TFP PVT Consortium underscores its growing presence in specialized war, terror and political violence coverage. This combination of upgraded earnings expectations and deeper involvement in complex...

Oklo Inc. recently announced that it was selected by the U.S. Department of Energy for advanced negotiations under the Surplus Plutonium Utilization Program, while also securing accelerated Nuclear Regulatory Commission approval of the Principal Design Criteria topical report for its Aurora powerhouse reactor. Together, these steps strengthen Oklo’s bid to turn surplus plutonium into usable fuel and streamline future licensing, directly affecting its long-term fuel and project...

Johnson & Johnson (NYSE:JNJ) reported multiple milestone clinical trial readouts at ASCO 2026 across autoimmunity, oncology, and myeloma. The company highlighted first in class efficacy signals for FcRn-blocker nipocalimab in systemic lupus erythematosus (SLE) and promising outcomes in Sjögren's disease. Phase 3 data for prostate cancer and myeloma therapies were described as practice changing in scope, with potential to influence future treatment standards and regulatory plans. For...

Recent progress in NextNav (NN) stock centers on its 5G positioning, navigation, and timing network, where field tests validated around 20 nanoseconds timing accuracy and FCC engagement advanced, along with a move to redeem public warrants. See our latest analysis for NextNav. The stock has pulled back 8.44% on a 1 day share price return to US$21.60. However, a 30 day share price return of 11.74% and a 1 year total shareholder return of 82.12% suggest momentum has largely been positive around...

StandardAero (SARO) shares came under pressure after the company outlined a CEO transition, and investors reacted to a research downgrade citing softer near term air-traffic expectations along with questions around the updated leadership plan. See our latest analysis for StandardAero. At a share price of US$25.61, StandardAero’s stock has come under pressure, with the 7 day share price return down 10.58% and the year to date share price return down 13.60%, while the 1 year total shareholder...

Recent performance and why Tyler Technologies is on investors’ radar Tyler Technologies (TYL) has come into focus after a challenging stretch for the stock, with shares down over the past month, past 3 months, year to date, and past year. At a last close of US$312.07 and a market value of about US$13b, the company now sits against a backdrop of mixed return history and solidly positive reported revenue and net income figures. See our latest analysis for Tyler Technologies. The share price has...

Why Aeluma (ALMU) is Drawing Attention Now Aeluma (ALMU) has come onto investors’ radar after a recent period of mixed share performance, including a move down 17% in the latest session. This has prompted closer inspection of its fundamentals and recent trading trends. See our latest analysis for Aeluma. While the latest 1 day share price return of down 16.98% to US$22.59 grabs attention, the 90 day share price return of 50.40% and 3 year total shareholder return of about 7x show momentum has...